Cidara Therapeutics Inc (CDTX):企業の財務・戦略的SWOT分析

◆英語タイトル:Cidara Therapeutics Inc (CDTX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH2305574FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥64,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥97,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cidara Therapeutics Inc (Cidara), formerly K2 Therapeutics Inc is a biotechnology company that discovers, develops and commercializes novel anti-infectives including immunotherapies. The company’s pipeline products include CD101 for treatment of invasive fungal disease; and CD377 for treating influenza. The company is investigation RSV AVC program for treatment of respiratory syncytial virus (RSV); HIV AVC for human immunodeficiency viruses (HIV); CoV AVC for pan corona virus. Cidara proprietary Cloudbreak, an antiviral platform to the fight against life-threatening infectious disease that provides potent antiviral activity and immune system engagement in a single molecule. The company works in collaboration with Mundipharma International Ltd to develop and commercialize rezafungin for the treatment and prevention of invasive fungal disease. Cidara is headquartered in San Diego, California, the US.

Cidara Therapeutics Inc Key Recent Developments

Apr 07,2021: Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Apr 05,2021: Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza
Apr 01,2021: Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 03,2021: Cidara Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 25,2021: Cidara Therapeutics provides corporate update and reports fourth quarter and full year 2020 financial results

This comprehensive SWOT profile of Cidara Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Cidara Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Cidara Therapeutics Inc – Key Information
Cidara Therapeutics Inc – Overview
Cidara Therapeutics Inc – Key Employees
Cidara Therapeutics Inc – Key Employee Biographies
Cidara Therapeutics Inc – Key Operational Heads
Cidara Therapeutics Inc – Major Products and Services
Cidara Therapeutics Inc – History
Cidara Therapeutics Inc – Company Statement
Cidara Therapeutics Inc – Locations And Subsidiaries
Cidara Therapeutics Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Cidara Therapeutics Inc – Business Description
Cidara Therapeutics Inc – Corporate Strategy
Cidara Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Cidara Therapeutics Inc – Strengths
Cidara Therapeutics Inc – Weaknesses
Cidara Therapeutics Inc – Opportunities
Cidara Therapeutics Inc – Threats
Cidara Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Cidara Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Cidara Therapeutics Inc, Key Information
Cidara Therapeutics Inc, Key Ratios
Cidara Therapeutics Inc, Share Data
Cidara Therapeutics Inc, Major Products and Services
Cidara Therapeutics Inc, History
Cidara Therapeutics Inc, Key Employees
Cidara Therapeutics Inc, Key Employee Biographies
Cidara Therapeutics Inc, Key Operational Heads
Cidara Therapeutics Inc, Other Locations
Cidara Therapeutics Inc, Subsidiaries
Cidara Therapeutics Inc, Key Competitors
Cidara Therapeutics Inc, SWOT Analysis
Cidara Therapeutics Inc, Ratios based on current share price
Cidara Therapeutics Inc, Annual Ratios
Cidara Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Cidara Therapeutics Inc (CDTX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • JP Elektroprivreda BiH d.d. Sarajevo (JPESR)-エネルギー分野:企業M&A・提携分析
    Summary JP Elektroprivreda BiH d.d. Sarajevo (Elektroprivreda BiH) is a utility company that generates, transmits, supplies, and trades electricity. It also exports and imports electricity, including the management of electricity system. The company generates electricity from coal and hydro sources. …
  • Berkshire Hathaway Energy Co:石油・ガス:M&Aディール及び事業提携情報
    Summary Berkshire Hathaway Energy Company (BHE) a subsidiary of Berkshire Hathaway Inc., generates, transmits, stores, distributes, and supplies electricity; and procures, transports, distributes and sells natural gas through its subsidiaries. It generates power through diversified energy sources su …
  • PT Kalbe Farma Tbk (KLBF):製薬・医療:M&Aディール及び事業提携情報
    Summary PT Kalbe Farma Tbk (Kalbe) provides a wide range of healthcare solutions. The company undertakes the development, manufacturing and distribution of prescription pharmaceutical products, consumer health products, nutritional products and healthcare services. Its product portfolio comprises br …
  • Ardelyx Inc (ARDX):企業の財務・戦略的SWOT分析
    Summary Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company offers products such as tenapanor, and RDX013. Its products are used for hyperphosphatemia in patients with end-stage renal disease; consti …
  • Dynegy Inc.:企業の戦略・SWOT・財務情報
    Dynegy Inc. - Strategy, SWOT and Corporate Finance Report Summary Dynegy Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Align Technology, Inc.:戦略・SWOT・企業財務分析
    Align Technology, Inc. - Strategy, SWOT and Corporate Finance Report Summary Align Technology, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Eby-Brown Company LLC:企業の戦略・SWOT・財務情報
    Eby-Brown Company LLC - Strategy, SWOT and Corporate Finance Report Summary Eby-Brown Company LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nippon Soda Co., Ltd.:企業の戦略・SWOT・財務情報
    Nippon Soda Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Soda Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Parsons Corporation:企業の戦略・SWOT・財務分析
    Parsons Corporation - Strategy, SWOT and Corporate Finance Report Summary Parsons Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Ypsomed Holding AG (YPSN)-医療機器分野:企業M&A・提携分析
    Summary Ypsomed Holding AG (Ypsomed) is a medical device company. It designs, develops and manufactures injection systems. Its offers pen injectors, autoinjectors, dual chamber pens and other custom products. The company also offers contract manufacturing, industrial design, human factors engineerin …
  • Helios and Matheson Analytics Inc (HMNY):企業の財務・戦略的SWOT分析
    Summary Helios and Matheson Analytics Inc (Helios and Matheson) is a big data company. It offers IT infrastructure, social data aggregation, cognitive computing, map-tech innovation, application development, pattern discovery solutions. The company's analytic solutions find application across a broa …
  • Premier Farnell Ltd:企業の戦略的SWOT分析
    Premier Farnell Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Shangri-La Asia Ltd:戦略・SWOT・企業財務分析
    Shangri-La Asia Ltd - Strategy, SWOT and Corporate Finance Report Summary Shangri-La Asia Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • AK Transneft (TRNFP):石油・ガス:M&Aディール及び事業提携情報
    Summary AK Transneft (Transneft) is a midstream oil and gas pipeline company that specializes in the transportation of crude oil and refined petroleum products. The company transports oil and oil products through trunk pipelines in the Russian Federation and outside. It carries out preventive mainte …
  • Northern Vertex Mining Corp:企業の戦略・SWOT・財務分析
    Northern Vertex Mining Corp - Strategy, SWOT and Corporate Finance Report Summary Northern Vertex Mining Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Tana Exploration Company LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Tana Exploration Company LLC (Tana Exploration) is an oil and gas exploration and development company that develops oil and gas resources. The company's products include natural gas and crude oil. It provides services such as technical support, financial support, and remodeling services. Tan …
  • Pharmathen Global BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmathen Global BV (Pharmathen) is a pharmaceutical company with focus on the research and development of generics, active pharmaceutical ingredients (APIs), and finished formulations. Its vast product portfolio includes antibiotics, antimycotics, antivirals, antidiabetics and topical pain …
  • Janus Henderson Group Plc:企業の戦略・SWOT・財務情報
    Janus Henderson Group Plc - Strategy, SWOT and Corporate Finance Report Summary Janus Henderson Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • South Jersey Industries, Inc. (SJI):石油・ガス:M&Aディール及び事業提携情報
    Summary South Jersey Industries Inc (SJI) is an energy services holding company that sources and supplies natural gas and electricity. It develops, owns, and operates on-site energy production facilities. The company provides wholesale commodity marketing and fuel management services; and also offer …
  • bioMerieux Inc:医療機器:M&Aディール及び事業提携情報
    Summary bioMerieux Inc (bioMerieux), a subsidiary of Institut Merieux SA is a provider of diagnostic solutions. The company offers its products for clinical solutions which include blood culture, cancer diagnostics, cardiovascular disease, cardiovascular pathology, clinical laboratories, companion d …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆